Pauline Schneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pauline Schneider has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Rob Pieters
Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands
3 shared publications - Ronald W. Stam
Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands
2 shared publications - Anjo J. P. Veerman
Department of Pediatrics, Division of Pediatric Hematology/Oncology, VU University Medical Center, Amsterdam, The Netherlands
1 shared publication - Anton W. Langerak
Laboratory Medical Immunology, Department of Immunology Erasmus MC Rotterdam the Netherlands
1 shared publication - Dominique J.P.M. Stumpel
Department of Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital Rotterdam, Wytemaweg 80, P.O. Box 2060, 3000 CB Rotterdam, The Netherlands
1 shared publication Elisabeth R Van Wering
1 shared publication
Latest Publications
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (14) , 2008-2021
The potential of clofarabine in MLL -rearranged infant acute lymphoblastic leukaemia
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (14) , 2008-2021
The potential of clofarabine in MLL -rearranged infant acute lymphoblastic leukaemia
- 3 April 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50 (9) , 1665-1674
Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101
- 3 April 2014
- Published by Elsevier in European Journal of Cancer
- Vol. 50 (9) , 1665-1674
Glucocorticoid sensitisation in Mixed Lineage Leukaemia-rearranged acute lymphoblastic leukaemia by the pan-BCL-2 family inhibitors gossypol and AT-101
- 1 September 2006
- Vol. 91 (9) , 1212-21
The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols.
Subgroups of T-cell acute lymphoblastic leukemia (T-ALL), defined according to recurrent cytogenetic aberrations, may have different prognoses. The aim of this study was to determine the prognostic relevance of molecular-cytogenetic abnormalities in pediatric patients using quantitative real-time polymerase chain reaction and fluorescence in situ hybridization. The patients were assigned to TAL1, HOX11/TLX1, HOX11L2/TLX3, or CALM-AF10 subgroups. The cytogenetic subgroups were characterized in relation to immunophenotype and the expression of aberrantly expressed transcription factors. In our cohort study, CALM-AF10 was associated with an immature immunophenotype and poor outcome (p=0.005). HOX11L2 was associated with both immunophenotypically immature cases as well as cases committed to the gammadelta-lineage. HOX11L2 was significantly associated with poor outcome (p=0.01), independently of the expression of CD1 or the presence of NOTCH1 mutations. TAL1 abnormalities were associated with alphabeta-lineage commitment, and tended to be associated with a good outcome. Cells in HOX11 cases resembled early CD1-positive cortical thymocytes without expression of Cytbeta and TCR molecules. In relation to the expression of early T-cell transcription factors, high TAL1 levels were found in immunophenotypically-advanced cases, whereas high LYL1 levels were found in immature subgroups. The reported outcomes for HOX11L2-rearranged T-ALL cases are conflicting; the prognostic impact may depend on the therapy given. In our cohort, this cytogenetic aberration was associated with a poor outcome. Our data on CALM-AF10 rearranged T-ALL, albeit based on only three patients, suggest that this type of leukemia is associated with a poor outcome.
- 1 September 2006
- Vol. 91 (9) , 1212-21
The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols.
Subgroups of T-cell acute lymphoblastic leukemia (T-ALL), defined according to recurrent cytogenetic aberrations, may have different prognoses. The aim of this study was to determine the prognostic relevance of molecular-cytogenetic abnormalities in pediatric patients using quantitative real-time polymerase chain reaction and fluorescence in situ hybridization. The patients were assigned to TAL1, HOX11/TLX1, HOX11L2/TLX3, or CALM-AF10 subgroups. The cytogenetic subgroups were characterized in relation to immunophenotype and the expression of aberrantly expressed transcription factors. In our cohort study, CALM-AF10 was associated with an immature immunophenotype and poor outcome (p=0.005). HOX11L2 was associated with both immunophenotypically immature cases as well as cases committed to the gammadelta-lineage. HOX11L2 was significantly associated with poor outcome (p=0.01), independently of the expression of CD1 or the presence of NOTCH1 mutations. TAL1 abnormalities were associated with alphabeta-lineage commitment, and tended to be associated with a good outcome. Cells in HOX11 cases resembled early CD1-positive cortical thymocytes without expression of Cytbeta and TCR molecules. In relation to the expression of early T-cell transcription factors, high TAL1 levels were found in immunophenotypically-advanced cases, whereas high LYL1 levels were found in immature subgroups. The reported outcomes for HOX11L2-rearranged T-ALL cases are conflicting; the prognostic impact may depend on the therapy given. In our cohort, this cytogenetic aberration was associated with a poor outcome. Our data on CALM-AF10 rearranged T-ALL, albeit based on only three patients, suggest that this type of leukemia is associated with a poor outcome.